How to Buy Insulet Stock
Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
Insulet stock last closed at $315.78, up 1.74% from the previous day, and has increased 64.73% in one year. It has overperformed other stocks in the Medical Devices industry by 0.86 percentage points. Insulet stock is currently +75.13% from its 52-week low of $180.31, and -4.11% from its 52-week high of $329.33.
As of Aug 14, 2025, there are 70.39M PODD shares outstanding. The market cap of PODD is $22.23B. In the last 24 hours, 764,000 PODD shares were traded.
How to Buy Insulet Stock
Not sure how to invest in Insulet stock? Here's how.
- Decide where to buy Insulet stock: You need to choose a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you determine where to buy Insulet stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Put funds into your brokerage account: Choose your payment method and add your info.
- Research Insulet stock: The Insulet ticker symbol is PODD. Is Insulet stock a good investment? Should you buy shares of PODD? How do PODD's underlying business fundamentals look? Do top analysts think Insulet is a good buy? Why has PODD's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if PODD is a good stock to buy).
- Execute your PODD purchase: Decide if you will purchase PODD shares at the current market price or use a limit order to buy PODD shares at a given price.
- Get notifications regarding your PODD position: Create a watchlist to monitor your position in Insulet shares.
Step 1: Decide where to buy Insulet stock
You will need an online brokerage account to access the NASDAQ market and buy PODD stock.
Our favorite brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen the right brokerage, you need to fill out some personal information so you are able to buy PODD stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to create your new brokerage account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have filled out your info on a good online stock trading app, your next step is to transfer the money for your investment:
Watch the walkthrough below to see the process of depositing funds into your new investment account.
Step 4: Research Insulet stock
Once you have chosen the best place to buy Insulet stock, it's critical to analyze their stock before you invest, so you can wrap your head around the risk and opportunity.
Overview of key PODD info
PODD Overview
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis.
You can view all of the due diligence checks on PODD's stock page.
What is the fair value of PODD stock?
You can use a variety of different financial metrics, analyses, models, and charts to gauge PODD's true value.
Using relative valuations ratios:
- PODD could be overvalued based on its P/E ratio of 93.7x, relative to Medical Devices industry P/E ratio of 31.59x
- PODD could be overvalued based on its P/B ratio of 15.19x, relative to Medical Devices industry P/B ratio of 3.98x
- PODD could be overvalued based on its PEG ratio of 3.28x
You can access additional valuation analysis on PODD's stock here.
PODD Financial Health Overview
Passed Financial Due Diligence Checks:
- PODD earnings of $320.50M is not enough to cover its interest payments.
- There are more short-term assets than long-term liabilities on the PODD balance sheet.
- Total PODD debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the PODD balance sheet.
- PODD's operating cash flow of $506.50M allows it to safely service it's debt of $1.40B.
Failed Financial Due Diligence Checks:
- PODD has a relatively high debt to equity ratio of 1.37.
- PODD profit margin has gone down from 21.1% to 10% in the past year.
Is it a good time to buy Insulet stock, according to Wall Street analysts?
Out of 13 Wall Street analysts who track PODD, the consensus analyst rating on Insulet is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Latest PODD Analyst Upgrades/Downgrades
Jayson Bedford, a top 14% analyst from Raymond James maintains PODD with a buy rating and raises their PODD price target from $328.00 to $360.00, on May 27, 2025.
Joanne Wuensch, a top 7% analyst from Citigroup maintains PODD with a strong buy rating and raises their PODD price target from $320.00 to $380.00, on May 22, 2025.
Citigroup's Joanne Wuensch raised their price target on Insulet (NASDAQ: PODD) by 18.8% from $320 to $380 on 2025/05/22. The analyst maintained their Strong Buy rating on the stock.
Insulet reported its Q1 2025 earnings on 2025/05/07.
Citigroup replaced Insulet with Edwards Lifesciences as its sector Top Pick, Wuensch told readers.
The analyst explained that they removed Insulet as their firm's top pick because the stock has dipped 25% YTD and over 72% in the past twelve months.
Earnings Report
For Q1 2025, Insulet reported:
- EPS of $1.02, which beat the Zacks Consensus Estimate of $0.81 and, by 39.7%, Q1 2024’s $0.73.
- Revenue of $569M, which beat the Zacks Consensus Estimate by 4.96% and, by 28.8%, Q1 2024’s $441.7M.
Management guided:
For Q2 2025:
- Revenue growth of 24% to 27%.
For FY 2025:
- Revenue growth of 20% to 23%.
President & CEO Ashley McEvoy commented: “Our Q1 results showcase the strong execution and dedication of the Insulet team, who have continued to expand the reach of Omnipod 5 technology to people living with diabetes globally.
“As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our Podders.
“Insulet is just starting an exciting journey to revolutionize diabetes management globally.
“I am energized and honored to embark on that journey with all of you.”
Mike Polark, a top 20% analyst from Wolfe Research upgrades PODD to a buy rating and announces their PODD price target of $350.00, on May 13, 2025.
Steven Lichtman, a top 38% analyst from Oppenheimer maintains PODD with a buy rating and raises their PODD price target from $312.00 to $324.00, on May 9, 2025.
Matt Miksic, a bottom 5% analyst from Barclays maintains PODD with a hold rating and raises their PODD price target from $234.00 to $266.00, on Apr 30, 2025.
You can dig deeper into what analysts are saying on the Insulet stock forecast page.
PODD Trading Indicators
How is PODD performing as a company?
Last year, PODD earnings were $236.10M. In the last five year, PODD's earnings have increased by 64.47% per year. This was faster than the Medical Devices industry average of 30.28%.
Last year, PODD revenue was $2.36B. During the past 5 year, PODD's revenue has increased by 23.36% per year. This was faster than the Medical Devices industry average of 10.46%.
You can research PODD's earnings and revenue performance here.
Who is buying/selling PODD?
Over the last 12 months, insiders at PODD have sold more shares than they have bought.
Prem Singh, SVP Global Operations of PODD, was the latest PODD insider to buy. They bought $154,843.65 worth of PODD shares on Aug 7, 2025.
Dig into more about who owns PODD stock here.
Can I rely on PODD as an income stream?
No, Insulet doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your PODD purchase
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly fine for most investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a particular dollar amount limit, place a limit order.
Hit the Open button and eToro will execute the order.
If you need more help investing in stocks on eToro, watch the how to video below:
Step 6: Get notifications regarding your PODD position
Now that you own some shares in PODD, you'll want to stay up-to-date on your new investment.
Add PODD to a watchlist to see the latest developments about your PODD stock.
PODD Feed
How to Buy Stock in Insulet
To reiterate, here are the 6 steps to buy Insulet stock:
- Decide where to buy Insulet stock
- Open a brokerage account
- Put funds into your brokerage account
- Research Insulet stock
- Execute your PODD purchase
- Get notifications regarding your PODD position
If you require a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to get notifications regarding your investment in Insulet, create a watchlist today.
Other "How To" Guides You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.